deltatrials
Completed PHASE3 NCT00036335

Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain

Duloxetine Hydrochloride (LY248686) Protocol F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain

Sponsor: Eli Lilly and Company

Conditions Depression Pain
Interventions Duloxetine Hydrochloride
Updated 5 times since 2017 Last updated: Jul 18, 2006 Started: Mar 31, 2002 Completion: Jan 31, 2003

Listed as NCT00036335, this PHASE3 trial focuses on Depression and Pain and remains completed. Sponsored by Eli Lilly and Company, it has been updated 5 times since 2002, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Atlanta, United States, Austin, United States, Brown Deer, United States, Burbank, United States, Cincinnati, United States, Clementon, United States, Farmington Hills, United States, Fresno, United States, Glen Burnie, United States and 15 more location s